

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** (Not for submission under 37 CFR 1.99)

Application Number		10590672
Filing Date		2007-10-23
First Named Inventor	Kung	
Art Unit	1642	
Examiner Name	Lei Yao	
Attorney Docket Number	20363-025 NATL	

## **U.S. PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

## **U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10590672
Filing Date	2007-10-23
First Named Inventor	Kung
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	20363-025 NATL

LY	1	ARCARO, A., et al: "Potent inhibition of human atypical teratoid/rhabdoid tumor growth by the novel insulin-like growth factor receptor inhibitor NVP-AEW541", Mol Mind (February 17, 19, Zurich) 2005, abst. P004	<input type="checkbox"/>
	2	CAPRARO, H-G, et al: "Synthesis and SAR of 5,7-disubstituted pyrrolo[2,3-d]pyrimidine derivatives, a class of highly potent and selective Insulin-like Growth Factor 1 Receptor (IGF-1R) Inhibitors", Drugs Fut, 29(Suppl. A), P111 (2004) ABSTRACT ONLY	<input type="checkbox"/>
	3	FERREIRA BRANDAO GUERREIRO, A.S., et al: "Targeting IGF-IR in human neuroblastoma: Potent antitumor activity of the novel inhibitor NVP-AEW541", Mol Mind (February 17-19, Zurich) 2005, P039 ABSTRACT ONLY	<input type="checkbox"/>
	4	GARCIA-ECHEVERRIA, C.: "Targeted anti-cancer drugs - dream or reality?", CNIO Symposium: Molecular Taxonomy of Cancer (February 3-6, Madrid) 2004, ABSTRACT ONLY	<input type="checkbox"/>
	5	GARCIA-ECHEVERRIA, C., et al: "The discovery of potent and selective insulin-like growth factor I receptor kinase inhibitors", 29th Natl Med Chem Symp (June 27-July 1, Madison) 2004, Abst 58	<input type="checkbox"/>
	6	GARCIA-ECHEVERRIA, C., et al: "In vivo antitumor activity of NVP-AEW541 - A novel, potent, and selective inhibitor of the IGF-IR kinase", Cancer Cell, 5(3): 231-239 (2004)	<input type="checkbox"/>
	7	GARCIA-ECHEVERRIA, C., et al: "NVP-AEW541 - a novel, potent and selective inhibitor of the IGF-1R kinase", MMRF Res Roundtable: Novel Target Ther Treat Multiple Myeloma (April 20-21, Torino) (2004) ABSTRACT ONLY	<input type="checkbox"/>
	8	KRYSTAL, G., et al: "Small molecule receptor tyrosine kinase inhibitors delineate a spectrum of dependence of SCLC cell lines on IGF-1 and SCF signaling", 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (November 17-21, Boston) 2003, Abst B159	<input type="checkbox"/>
	9	KRYSTAL, G.W., et al: "The IGF-1R kinase inhibitor NVP-ADW742 sensitizes small cell lung cancer cell lines to the effects of chemotherapy", Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 5040	<input type="checkbox"/>
	10	MITSIADES, C., et al: "IGF-1 receptor inhibition: A novel therapeutic strategy for multiple myeloma", MMRF Res Roundtable: Novel Target Ther Treat Multiple Myeloma (April 20-21, Torino) 2004, Abst	<input type="checkbox"/>
	11	MITSIADES, C., et al: "Characterization of selective small molecule kinase inhibitors of IGF-IR and their in vitro and in vivo activity against multiple myeloma, other hematologic malignancies and solid tumors", 15th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (November 17-21, Boston) 2003, Abst A280	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10590672
Filing Date	2007-10-23
First Named Inventor	Kung
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	20363-025 NATL

LY	12	MITSIADIS, C.S., et al, "The IGF/IGF-1R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors", Proc Am Assoc Cancer Res (AACR) 2003, 44(2nd ed): Abst 4005	<input type="checkbox"/>
	13	MITSIADIS, N., et al: "NVP-AEW541: A selective small molecule IGF-1R tyrosine kinase inhibitor is active against multiple myeloma and other hematologic neoplasias and solid tumors", Blood 2004, 104(11, Part 1): Abst 766	<input type="checkbox"/>
	14	O'REILLY, K., et al: "The abrogation of rapamycin-induced AKT activity by the small molecule IGF-1R inhibitor, AEW541, and the enhanced antitumor activity of combined mTOR and IGF-1R inhibition", Eur J Cancer Suppl 2004, 2(8): Abst 388	<input type="checkbox"/>
	15	SCHNELL, C., et al: "Characterization of the effects of a small molecular weight inhibitor on IGF-I induced angiogenesis", Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 1529	<input type="checkbox"/>
	16	SCOTLANDI, K., et al: "Effectiveness of a novel, selective inhibitor of the IGF-1R kinase against musculoskeletal tumors", Eur J Cancer Suppl 2004, 2(8): Abst 340	<input type="checkbox"/>
	17	WARSHAMANA-GREENE, G.S., et al: "The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy", Clin Cancer Res, 11(4): 1563-1571 (2005)	<input type="checkbox"/>
	18	Warshamana-Green, G.S., et al: "The novel IGF-1R kinase inhibitor NVP-ADW742 acts synergistically with STI571 and etoposide to block PI3K-Akt activity, inhibit growth and promote apoptosis in SCLC", Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 3685	<input type="checkbox"/>
	19	WARSHAMANA-GREEN, G.S., et al: "The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling", Mol. Cancer Ther., 3(5): 527-535 (2004)	<input type="checkbox"/>
	20	ZHAO Y., et al: "IGF-I receptor kinase inhibitor NVP-AEW541-NX-7 abolishes MCF-7 breast cancer cell responsivity to estradiol", Eur J Cancer Suppl 2004, 2(8): Abst 357	<input type="checkbox"/>
↓	21	"Inhibitors of signal transduction pathways", 373522, Drug Data Report 2004, 26(10), pg. 966-967	<input type="checkbox"/>
	22		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application Number	10590672
	Filing Date	2007-10-23
	First Named Inventor	Kung
	Art Unit	1642
	Examiner Name	Lei Yao
Attorney Docket Number		20363-025 NATL

If you wish to add additional non-patent literature document citation information please click the Add button			
<b>EXAMINER SIGNATURE</b>			
Examiner Signature	Lei Yao	Date Considered	11/30/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
<small> <sup>1</sup>See Kind Codes of USPTO Patent Documents at <a href="http://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup>Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.  <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language translation is attached.       </small>			